<?xml version="1.0" encoding="UTF-8"?>
<p>These latest data regarding RDV efficacy against SARS-CoV-2 infection are stimulating, although the gaps concerning its safety profile are rather wide at present, and the forthcoming results from the ongoing clinical trials are essential to fill them. On the basis of these considerations, it is recommended that, during the treatment, the physicians should be well-aware of the considerable number of factors/conditions (mainly in the case of severely ill patients with comorbidities—diabetes, cardiovascular pathology, and aged people) that might interfere with this compound and lead to adverse events. To prevent or to minimize any kind of undesired effects that might aggravate patients’ status, some key information about RDV pharmacokinetics, pharmacodynamics, and drug-drug interactions should be reviewed, data that will be provided in the following paragraphs.</p>
